VaibhavSahaiMDMS

PubMed

• Regorafenib in Patients With Solid Tumors WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
  Vaibhav Sahai, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vijay Suhag, Elie G Dib, Inderjit Mehmi, Kunal C Kadakia, Evan Pisick, Herbert L Duvivier, Phat Le...> ;JCO Precision Oncology. 2024 Apr 1
• Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer.
  Caleb Cheng, Jing Hu, Rahul Mannan, Rupam Bhattacharyya, Nicholas J Rossiter, Brian Magnuson, Jasmine P Wisniewski, Yang Zheng, Lanbo Xiao, Chungen Li, Dominik Awad, T...> ;Biorxiv. 2024 Mar 20
• A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
  Thomas Enzler, Jiaqi Shi, Jake McGue, Brian D Griffith, Lei Sun, Vaibhav Sahai, Hari Nathan, Timothy L Frankel> ;International Journal of Molecular Sciences. 2024 Mar 3
• Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer.
  Qiang Zhang, Long Jiang, Weiwei Wang, Amanda K Huber, Victoria M Valvo, Kassidy M Jungles, Erin A Holcomb, Ashley N Pearson, Stephanie The, Zhuwen Wang, Leslie A Parse...> ;JCI Insight. 2024 Feb 20
• Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
  Davis, E., Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L Coveler, Steven Powell, Bruno Bastos, Eli...> ;Clinical Cancer Research. 2024 Feb 1
• Are We There Yet? - Alternating Chemotherapy Regimens in Pancreatic Cancer.
  Vaibhav Sahai, Al B Benson> ;NEJM Evidence. 2024 Feb 1
• In-Depth Proteome Profiling of Small Extracellular Vesicles Isolated from Cancer Cell Lines and Patient Serum.
  Komal Abhange, Reta Birhanu Kitata, Jie Zhang, Yi-Ting Wang, Matthew J Gaffrey, Tao Liu, Valerie Gunchick, Valerie Khaykin, Vaibhav Sahai, Kyle C Cuneo, Neehar D Parik...> ;Journal of Proteome Research. 2024 Jan 5
• Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles.
  Javier Granados, Amy L Pasternak, N Lynn Henry, Vaibhav Sahai, Daniel L Hertz> ;Clinical Pharmacology and Therapeutics. 2024 Mar 1
• 1 citations
  KRT17High/CXCL8+ tumor cells display both classical and basal features and regulate myeloid infiltration in the pancreatic cancer microenvironment.
  Eileen S Carpenter, Padma Kadiyala, Ahmed M Elhossiny, Samantha B Kemp, Jay Li, Nina G Steele, Rémy Nicolle, Zeribe C Nwosu, Julia Freeman, Henry Dai, Daniel Paglia, W...> ;Clinical Cancer Research. 2023 Oct 18
• 17 citations
  NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
  Al B Benson, Michael I D'Angelica, Thomas Abrams, Daniel E Abbott, Aijaz Ahmed, Daniel A Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, David Binder, Mitesh ...> ;Journal of the National Comprehensive Cancer Network. 2023 Jul 1
• 12 citations
  RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
  Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B Barry Touré, Songping Zhao, Roberto Valverde, Patrick J O'Hearn, Demetri T Moustakas, Heike Schönherr, Na...> ;Cancer Discovery. 2023 Sep 6
• Genomics driven precision oncology in advanced biliary tract cancer improves survival.
  Chandan Kumar-Sinha, Pankaj Vats, Nguyen Tran, Dan R Robinson, Valerie Gunchick, Yi-Mi Wu, Xuhong Cao, Yu Ning, Rui Wang, Erica Rabban, Janice Bell, Sunita Shankar, Ra...> ;Neoplasia. 2023 Aug 1
• Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
  Amy L Pasternak, Robinson Seda, Joseph Lipa, Rachel L McDevitt, Oxana V Crysler, Paul L Swiecicki, Bryan J Schneider, Brett Vanderwerff, N Lynn Henry, John C Krauss, V...> ;Clinical Pharmacology and Therapeutics. 2023 Aug 1
• Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer.
  Abbott, M., Hadley, S., Schipper, M., Das, R., Sahai, V., Bednar, F., Evans, J., Lawrence, T., Cuneo, K.> ;Advances in Radiation Oncology. 2023 May 6
• 4 citations
  Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).
  Arathi Mohan, Kent A Griffith, Fulei Wuchu, David B Zhen, Chandan Kumar-Sinha, Oxana Crysler, David Hsiehchen, Thomas Enzler, Dominique Dippman, Valerie Gunchick, Abhi...> ;Clinical Cancer Research. 2023 Jul 5
• 2 citations
  Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy.
  Valerie Gunchick, Rachel L McDevitt, Elizabeth Choi, Katherine Winslow, Mark M Zalupski, Vaibhav Sahai> ;The Oncologist. 2023 Jun 2
• 8 citations
  Analysis of Donor Pancreata Defines the Transcriptomic Signature and Microenvironment of Early Neoplastic Lesions.
  Eileen S Carpenter, Ahmed M Elhossiny, Padma Kadiyala, Jay Li, Jake McGue, Brian D Griffith, Yaqing Zhang, Jacob Edwards, Sarah Nelson, Fatima Lima, Katelyn L Donahue,...> ;Cancer Discovery. 2023 Jun 2
• Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?"
  Vaibhav Sahai, Mark M Zalupski> ;Cancer. 2023 Apr 1
• Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early pre-neoplastic pancreatic lesions.
  Eileen S Carpenter, Ahmed M Elhossiny, Padma Kadiyala, Jay Li, Jake McGue, Brian Griffith, Yaqing Zhang, Jacob Edwards, Sarah Nelson, Fatima Lima, Katelyn L Donahue, W...> ;Biorxiv. 2023 Jan 15
• 19 citations
  A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
  Vaibhav Sahai, Kent A Griffith, Muhammad S Beg, Walid L Shaib, Devalingam Mahalingam, David B Zhen, Dustin A Deming, Mark M Zalupski> ;Cancer. 2022 Oct 1
• 2 citations
  Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer.
  Brittany Rupp, Sarah Owen, Harrison Ball, Kaylee Judith Smith, Valerie Gunchick, Evan T Keller, Vaibhav Sahai, Sunitha Nagrath> ;International Journal of Molecular Sciences. 2022 Jul 16
• 2 citations
  Retrospective Cohort Analysis of Aspirin Use and Venous Thromboembolism in Patients with Pancreatic Cancer and an Indwelling Central Venous Catheter.
  Richard King, Jordan Schaefer, Vaibhav Sahai, Kent A Griffith, Suman L Sood> ;TH Open. 2022 Jul 1
• 6 citations
  Survey of US Medical Oncologists' Practices and Beliefs RegardingTesting Before Fluoropyrimidine Chemotherapy.
  Kyoin Koo, Amy L Pasternak, N Lynn Henry, Vaibhav Sahai, Daniel L Hertz> ;JCO Oncology Practice. 2022 Jun 1
• 1 citations
  T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy.
  Chandan Kumar-Sinha, Vaibhav Sahai> ;Journal of the National Comprehensive Cancer Network. 2022 Feb 1
• 3 citations
  Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients.
  Sarah Owen, Emily Prantzalos, Valerie Gunchick, Vaibhav Sahai, Sunitha Nagrath> ;Biomedicines. 2022 Jan 11
• Join now to see all

Journal Articles

• Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors  
  Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology

Lectures

• Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recur... 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
• A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresec... 
  2019 ASCO Annual Meeting - 6/1/2019
• A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer. 
  2019 ASCO Annual Meeting - 6/1/2019